Gilberts, IL, United States of America

Grover Burkett

This inventor holds 1 USPTO granted patent. Top assignee: Fenwal, Inc.. Active years: 2026.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Grover Burkett: Innovator in Apheresis Technology

Introduction

Grover Burkett is a notable inventor based in Gilberts, Illinois. He has made significant contributions to the field of medical technology, particularly in apheresis procedures. His innovative work has led to advancements that enhance the efficiency and effectiveness of blood processing.

Latest Patents

Burkett holds a patent for "Systems and methods for converting an apheresis fluid processing circuit to single or double needle mode." This patent describes systems and methods for performing apheresis procedures, including photopheresis. The technology utilizes a disposable fluid circuit that can be converted from a double needle configuration to a single needle configuration and vice versa. A controller directs the action of system pumps to clear potentially stagnant blood residing in the fluid circuit, tracks system parameters and status before and after conversion, and verifies that the procedure may proceed in its new configuration. He has 1 patent to his name.

Career Highlights

Burkett is currently employed at Fenwal, Inc., where he continues to develop innovative solutions in the medical field. His work has been instrumental in improving patient care through advanced apheresis technologies.

Collaborations

Some of his notable coworkers include Lan T Nguyen and Gregory Coultas, who have collaborated with him on various projects within the company.

Conclusion

Grover Burkett's contributions to apheresis technology exemplify the impact of innovation in the medical field. His work not only advances the technology but also enhances patient outcomes through improved procedures.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…